A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Melanoma
Head and Neck Carcinoma
Gastroesophageal Cancer
Breast Cancer
Pancreatic Adenocarcinoma
Colorectal Cancer
Biliary Tract Cancer

Interventions

DRUG: Selumetinib
DRUG: MEDI4736
DRUG: Tremelimumab

Sponsor

AstraZeneca